Larry R. Kaiser

Nonoperative thoracic duct embolization for traumatic thoracic duct leak: Experience in 109 patients

OBJECTIVEnTo demonstrate the efficacy of a minimally invasive, nonoperative, catheter-based approach to the treatment of traumatic chyle leak.nnnMETHODSnA retrospective review of 109 patients was conducted to assess the efficacy of thoracic duct embolization or interruption for the treatment of high-output chyle leak caused by injury to the thoracic duct.nnnRESULTSnA total of 106 patients presented with chylothorax, 1 patient presented with chylopericardium, and 2 patients presented with cervical lymphocele. Twenty patients (18%) had previous failed thoracic duct ligation. In 108 of 109 patients, a lymphangiogram was successful. Catheterization of the thoracic duct was achieved in 73 patients (67%). In 71 of these 73 patients, embolization of the thoracic duct was performed. Endovascular coils or liquid embolic agent was used to occlude the thoracic duct. In 18 of 33 cases of unsuccessful catheterization, thoracic duct needle interruption was attempted below the diaphragm. Resolution of the chyle leak was observed in 64 of 71 patients (90%) post-embolization. Needle interruption of the thoracic duct was successful in 13 of 18 patients (72%). In 17 of the 20 patients who had previous attempts at thoracic duct ligation, embolization or interruption was attempted and successful in 15 (88%). The overall success rate for the entire series was 71% (77/109). There were 3 (3%) minor complications.nnnCONCLUSIONnCatheter embolization or needle interruption of the thoracic duct is safe, feasible, and successful in eliminating a high-output chyle leak in the majority (71%) of patients. This minimally invasive, although technically challenging, procedure should be the initial approach for the treatment of a traumatic chylothorax.

Cerebrospinal Fluid Drainage During Thoracic Aortic Repair: Safety and Current Management

BACKGROUNDnThe benefit of cerebrospinal fluid (CSF) drainage during thoracic aortic repair has been established. Few studies, however, report management and safety of CSF drainage.nnnMETHODSnBetween September 1992 and August 2007, 1,353 repairs of the thoracic aorta were performed, with 82% using CSF drainage. The CSF drainage was not used in cases of rupture, acute trauma, infection, or prior paraplegia. Thirty-one percent (76 of 246) of patients without CSF drainage were repaired prior to standardized use. All drains were inserted by cardiovascular anesthesia staff. Repairs were performed using distal aortic perfusion with heparinization. Early management involved free drainage to maintain CSF pressure less than 10 mm Hg, but was later modified to limit CSF drainage unless neurologic deficit occurred.nnnRESULTSnCerebrospinal fluid drainage was technically achieved in 99.8% (1,105 of 1,107) of cases. The CSF catheter-related complications occurred in 1.5% (17 of 1,107) of patients. No spinal hematomas were observed. The CSF leaks with spinal headache, CSF leak without spinal headache, spinal headache, intracranial hemorrhage, catheter fracture, and meningitis occurred in 6 (0.54%), 1 (0.1%), 2 (0.2%), 5 (0.45%), 1 (0.1%), and 2 (0.2%) cases, respectively. Mortality from subdural hematoma was 40% (2 of 5), and from meningitis was 50% (1 of 2). Spinal headaches resolved with conservative management. All CSF leaks resolved, but 71% (5/7) required blood patches. Since implementation of a limited CSF drainage protocol, no subdural hematomas have been observed.nnnCONCLUSIONSnCerebrospinal fluid drainage for thoracic aortic repairs can be performed safely with excellent technical success. Perioperative management of CSF drains requires diligent monitoring and judicious drainage. Standardizing CSF management may be beneficial.

Outcomes of Acute Type A Aortic Dissection After Previous Cardiac Surgery

BACKGROUNDnReports on outcomes of acute type A aortic dissection (ATAAD) repair after previous cardiac surgery (PCS) are few. Some suggest no difference in mortality while others note decreased risk of free rupture due to adhesions. We analyzed our experience of ATAAD after PCS.nnnMETHODSnBetween January 1992 and March 2009 we repaired 330 patients with ATAAD. Of these, 49 (15%) patients had PCS: coronary artery bypass in 30 (61%), aortic valve replacement in 8 (16%), coronary artery bypass/aortic valve replacement in 5 (10%), aortic valve replacement-mitral repair in 1 (2%), aortic valve replacement-tricuspid repair in 1 (2%), and others in 4 (9%) patients. The ATAAD patients with and without PCS (primary) were compared.nnnRESULTSnThe PCS group was older (63 vs 58 years, p < 0.02), more frequently men (82% vs 67%, p < 0.04), and less likely to have aortic insufficiency (30% vs 47%, p < 0.05). Otherwise, the PCS group did not differ in clinical presentation, with similar malperfusion and tamponade. Operative procedures did not differ between groups except for repair of pulmonary artery fistula (4% vs 0%, p < 0.03), more use of Cabrol shunt (18% vs 3%), p < 0.03), and more frequent need for mechanical cardiac support in the PCS group (8% vs 3.6%, p < 0.04). The PCS group suffered more strokes (10% vs 2.5%, p < 0.03), temporary neurologic deficits (24% vs 10%, p < 0.007), and higher hospital mortality (31% vs 13.8%, p < 0.007) than the no-PCS group.nnnCONCLUSIONSnPatients with ATAAD after PCS exhibited similar risks for malperfusion, hypotension, and cardiac tamponade. This suggests that adhesions formed after PCS do not eliminate the risk of cardiac tamponade from aortic rupture. Although results from surgical repair are acceptable, justifying timely repair, mortality still remains higher than without prior history of cardiac surgery.

Improved left ventricular unloading and circulatory support with synchronized pulsatile left ventricular assistance compared with continuous-flow left ventricular assistance in an acute porcine left ventricular failure model.

OBJECTIVEnControversy exists regarding the optimal pumping method for left ventricular assist devices. The purpose of this investigation was to test the hypothesis that pulsatile left ventricular assist synchronized to the cardiac cycle provides superior left ventricular unloading and circulatory support compared with continuous-flow left ventricular assist devices at the same level of ventricular assist device flow.nnnMETHODSnSeven male pigs were used to evaluate left ventricular assist device function using the TORVAD synchronized pulsatile-flow pump (Windmill Cardiovascular Systems, Inc, Austin, Tex) compared with the Bio-Medicus BPX-80 continuous-flow centrifugal pump (Medtronic, Inc, Minneapolis, Minn). Experiments were carried out under general anesthesia, and animals were instrumented via a median sternotomy. Hemodynamic measurements were obtained in the control state and with left ventricular assistance using the TORVAD and BPX-80 individually. Left ventricular failure was induced with suture ligation of the mid-left anterior descending coronary artery, and hemodynamic measurements were repeated.nnnRESULTSnDuring left ventricular assist device support, mean aortic pressure and total cardiac output were higher and left atrial pressure was lower with pulsatile compared with continuous flow at the same ventricular assist device flow rate. During ischemic left ventricular failure, pulsatile left ventricular support resulted in higher total cardiac output (5.58xa0± 1.58 vs 5.12xa0± 1.19, Pxa0<xa0.05), higher mean aortic pressure (67.8xa0± 14 vs 60.2xa0± 10, Pxa0<xa0.05), and lower left atrial pressure (11.5xa0± 3.5 vs 13.9xa0± 6.0, Pxa0<xa0.05) compared with continuous flow at the same left ventricular assist device flow rate.nnnCONCLUSIONnSynchronized, pulsatile left ventricular assistance produces superior left ventricular unloading and circulatory support compared with continuous-flow left ventricular assist at the same flow rates.

Pneumomediastinum: etiology and a guide to diagnosis and treatment

BACKGROUNDnPneumomediastinum may be associated with mediastinal organ injury. The aim of this study was to identify predictive factors of mediastinal organ injury in patients with pneumomediastinum to guide diagnosis and treatment.nnnMETHODSnA retrospective review was conducted including patients aged ≥18 years with Current Procedural Terminology code 518.1 (interstitial emphysema) from 2005-2011.nnnRESULTSnThere were 279 of 343 patients (81%) with and 64 of 343 (19%) without history of trauma. In the trauma population, 13 patients (5%) were found to have mediastinal organ injuries, 10 (4%) had airway injuries, and 3 (1%) had esophageal injuries. In the nontrauma population, 36 patients (56%) had spontaneous pneumomediastinum, esophageal injuries were seen in 17 (27%), pneumothorax in 9 (14%), and airway injuries in 2 (3%). The predictors of esophageal injury were instrumentation (odds ratio [OR], 45.7; P < .0001), pleural effusion (OR, 10.5; P < .0001), and vomiting (OR, 9.3; P < .0001). Previous instrumentation was the most significant predictor of airway injury (OR, 9.05; P < .02).nnnCONCLUSIONSnMediastinal organ injury in patients with pneumomediastinum is uncommon. Patients presenting with pneumomediastinum without a history of instrumentation, pleural effusion, or vomiting most commonly do not have mediastinal organ injuries.

Thymomas II A Clinicopathologic Correlation of 250 Cases With a Proposed Staging System With Emphasis on Pathologic Assessment

We present 250 cases of thymomas with emphasis on their clinical staging and follow-up. The patients were 120 males and 130 females between the ages of 13 and 92 years. Surgical resection was performed and histopathologic material evaluated in every case. Grossly, the tumors resected varied in size from 3 to 20 cm in greatest diameter. According to our proposed staging system, 31 cases were stage 0, 128 were stage I, 70 stage II, and 21 stage III at the time of resection. Histologically, approximately 53% of thymomas were of mixed histologic types. Follow-up information ranging from 1 to 16 years was obtained, showing significant statistical P values of .044 and .016 for overall and recurrence-free survival, respectively. We consider that our proposed staging system offers better stratification of cases and improved histologic definitions for proper staging of cases of thymoma.

Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States.

BackgroundOur aim was to evaluate the changes in age, stage distribution, and overall survival (OS) of patients with esophageal adenocarcinoma (EAC) over time.MethodsPatients from the Surveillance, Epidemiology, and End Results (SEER) database aged ≥20 with invasive EAC, diagnosed from 1973–2003 were reviewed. Survival follow-up ended in 2006.ResultsThere were 11,620 patients; 6580 (57%) aged ≥65. The stage distribution was 22%, 35%, and 43% for localized, regional, and distant metastasis for patients aged <65, and 33%, 33%, and 34% for patients aged ≥65. The number of patients ≥65xa0years with localized stage increased over time. Three-year OS for localized, regional, and distant disease increased from 19%, 10%, and 1% in 1973–1976, to 34%, 13%, and 2% in 1987–1991, and to 45%, 25%, and 4% in 2002–2003 (Pxa0<xa00.001). A sub-analysis of 5475 patients from 1988–2002 showed better survival for patients with esophagectomy for all stages. Three-year OS for 2074 patients with esophagectomy improved every 5xa0years from 1988–2002 (39%, 43% to 54%, Pxa0<xa00.001). Stratified by stage, year and esophagectomy status, patients aged <65 had better survival compared to patients aged ≥65 (Pxa0<xa00.001).ConclusionsThere has been a substantial improvement in overall survival among patients with invasive EAC over the last 3 decades. Patients receiving esophagectomy had longer survival. Survival with esophagectomy improved in each time period. Although younger EAC patients were diagnosed at more advanced stages over time, they had better survival.

Intraoperative electromagnetic navigational bronchoscopic localization of small, deep, or subsolid pulmonary nodules

Background: Localizing small or deep pulmonary nodules or subsolid ground‐glass opacities often is difficult during video‐assisted thoracoscopic surgery (VATS) or robotic‐assisted thoracoscopic surgery (RATS). This can result in larger resections or conversion to thoracotomy. The goal of this study is to evaluate the role of electromagnetic navigational bronchoscopic localization (ENBL) as a safe and accurate intraoperative method to localize small, deep, or subsolid nodules. Methods: This is a single‐institution, single‐surgeon retrospective study of all patients (51) who underwent combined ENBL and resection of 54 nodules between May 2013 and August 2015. Localization was performed by intraoperative ENBL‐guided transbronchial injection of a liquid marker. The liquid marker used was methylene blue, either alone or in addition to indocyanine green and Isovue. A fiduciary also was added in 2 cases. Immediately after localization, the patients underwent VATS for evaluation before proceeding with RATS for anatomical sublobar resection. Results: The mean preoperative largest nodule diameter on computed tomography scan was 13.3 mm (range, 4–44 mm). The mean distance from the surface of the lung to the middle of the nodule was 22 mm (range, 4–38 mm). Thirty‐one nodules were solid (57.4%), whereas 23 were ground‐glass opacities (42.6%). ENBL successfully localized the nodules for initial sublobar resection in 53 of 54 nodules (98.1%). Minimally invasive thoracoscopic surgery was performed successfully in 49 of 51 patients (96.1%), by RATS in 47 (92.2%), and VATS in 2 (3.9%). Two patients required conversion to thoracotomy secondary to extensive adhesions. Of the 54 nodules, final diagnosis was adenocarcinoma in 32 (59.2%), metastatic disease in 7 (13%), squamous cell carcinoma in 2 (3.7%), neuroendocrine tumor in 2 (3.7%), and benign in 11 (20.3%). There were no operative mortalities. Morbidities included acute renal insufficiency in 2 patients and prolonged air leak requiring a Heimlich valve in 3 patients. Mean length of stay was 3.9 days. Conclusions: ENBL is a safe and accurate intraoperative modality for targeted sublobar resection of pulmonary nodules that are deemed difficult to localize.

Should asymptomatic enlarged thymus glands be resected

OBJECTIVEnPatients frequently have an enlarged thymus incidentally identified on imaging. We sought to determine whether thymectomy is appropriate in patients with diffusely enlarged thymus glands.nnnMETHODSnA retrospective review was conducted of patients undergoing thymectomy without myasthenia gravis at 1 institution over 15 years.nnnRESULTSnOf 117 patients undergoing thymectomy, 109 patients had complete data. Thirty-six had a gland judged by the surgeon to be diffusely enlarged, and 73 had a discrete mass. Of the 36 diffusely enlarged thymus glands, 18 (50%) occurred in patients with no symptoms referable to the thymus. No patient (0/18; 0%) with an asymptomatic diffusely enlarged thymus gland had a pathologic diagnosis that would have required resection (8 normal; 10 hyperplasia). Of the 18 symptomatic patients with diffusely enlarged glands, 4 (22.2%) harbored lymphoma, but none harbored thymoma or other tumor (Pxa0<xa0.05; symptomatic vs asymptomatic). Of the 73 patients with discrete masses, 45 (61.6%) were symptomatic, and both the symptomatic and asymptomatic patients had a high rate of pathologic diagnoses that represented an indication for resection (53.3% and 42.8%, respectively, harbored thymoma or other tumor). Of the 25 (of 109) patients initially having a diagnosis of thymic hyperplasia, only 3 (12%) had true follicular hyperplasia on re-review of the pathologic condition. Interestingly, an autoimmune disorder developed in 2 (67%) of these 3 patients on long-term follow-up.nnnCONCLUSIONSnAsymptomatic patients with diffusely enlarged thymus glands can be followed up expectantly because they have a negligible incidence of significant thymic disease; symptomatic patients with diffusely enlarged thymus glands may have lymphoma, so biopsy is appropriate. Half of patients with a discrete mass have tumors requiring resection; imaging advances would be useful to better differentiate among patients within this group.

The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients

We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk‐adjusted all‐cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no‐induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7% versus 6.5% versus 6.2%, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95% confidence interval 0.67–0.95, p = 0.009) and basiliximab induction (0.88, 0.80–0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7% versus 55.4 versus 55.9%), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS.